149 related articles for article (PubMed ID: 20010366)
1. Section E6.5 of the ACMG technical standards and guidelines: chromosome studies for solid tumor abnormalities.
Cooley LD; Mascarello JT; Hirsch B; Jacky PB; Rao PN; Saxe D; Rao KW;
Genet Med; 2009 Dec; 11(12):890-7. PubMed ID: 20010366
[TBL] [Abstract][Full Text] [Related]
2. Section E6.5-6.8 of the ACMG technical standards and guidelines: chromosome studies of lymph node and solid tumor-acquired chromosomal abnormalities.
Cooley LD; Morton CC; Sanger WG; Saxe DF; Mikhail FM
Genet Med; 2016 Jun; 18(6):643-8. PubMed ID: 27124786
[TBL] [Abstract][Full Text] [Related]
3. Section E6.1-6.4 of the ACMG technical standards and guidelines: chromosome studies of neoplastic blood and bone marrow-acquired chromosomal abnormalities.
Mikhail FM; Heerema NA; Rao KW; Burnside RD; Cherry AM; Cooley LD
Genet Med; 2016 Jun; 18(6):635-42. PubMed ID: 27124785
[TBL] [Abstract][Full Text] [Related]
4. Section E6.7-6.12 of the American College of Medical Genetics and Genomics (ACMG) Technical Laboratory Standards: Cytogenomic studies of acquired chromosomal abnormalities in solid tumors.
Church AJ; Akkari Y; Deeb K; Kolhe R; Lin F; Spiteri E; Wolff DJ; Shao L;
Genet Med; 2024 Apr; 26(4):101070. PubMed ID: 38376505
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic Nomenclature and Reporting.
Stevens-Kroef M; Simons A; Rack K; Hastings RJ
Methods Mol Biol; 2017; 1541():303-309. PubMed ID: 27910032
[TBL] [Abstract][Full Text] [Related]
6. [Value of molecular cytogenetics in pre- and postnatal diagnostic of chromosome abnormalities].
Romana SP; Gosset P; Elghezal H; Le Lorc'h M; Ozilou C; Lapierre JM; Sanlaville D; Brisset S; Turleau C; Vekemans M
J Gynecol Obstet Biol Reprod (Paris); 2001 Feb; 30(1 Suppl):75-9. PubMed ID: 11240520
[No Abstract] [Full Text] [Related]
7. Standardized fluorescence in situ hybridization testing based on an appropriate panel of probes more effectively identifies common cytogenetic abnormalities in myelodysplastic syndromes than conventional cytogenetic analysis: a multicenter prospective study of 2302 patients in China.
Lai YY; Huang XJ; Li J; Zou P; Xu ZF; Sun H; Shao ZH; Zhou DB; Chen FP; Liu ZG; Zhu HL; Wu DP; Wang C; Zhang Y; Li Y; Hou M; Du X; Wang X; Li W; Lai YR; Zhou J; Zhou YH; Fang MY; Qiu L; Wang XM; Zhang GS; Jiang M; Liang YM; Zhang LS; Chen XQ; Bai H; Lin JY
Leuk Res; 2015 May; 39(5):530-5. PubMed ID: 25823643
[TBL] [Abstract][Full Text] [Related]
8. Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?
Peterson JF; Aggarwal N; Smith CA; Gollin SM; Surti U; Rajkovic A; Swerdlow SH; Yatsenko SA
Oncotarget; 2015 Aug; 6(22):18845-62. PubMed ID: 26299921
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic analysis and reporting.
Campbell LJ
Methods Mol Biol; 2011; 730():259-68. PubMed ID: 21431647
[TBL] [Abstract][Full Text] [Related]
10. Section E6.1-6.6 of the American College of Medical Genetics and Genomics (ACMG) Technical Laboratory Standards: Cytogenomic studies of acquired chromosomal abnormalities in neoplastic blood, bone marrow, and lymph nodes.
Akkari Y; Baughn LB; Kim A; Karaca E; Raca G; Shao L; Mikhail FM;
Genet Med; 2024 Apr; 26(4):101054. PubMed ID: 38349293
[TBL] [Abstract][Full Text] [Related]
11. [Impact of tumorcytogenetics in tumor diagnostics].
Wenzel F; Röthlisberger B
Ther Umsch; 2008 Sep; 65(9):473-80. PubMed ID: 18791960
[TBL] [Abstract][Full Text] [Related]
12. Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do?
Costa D; Valera S; Carrió A; Arias A; Muñoz C; Rozman M; Belkaid M; Coutinho R; Nomdedeu B; Campo E
Leuk Res; 2010 Nov; 34(11):1437-41. PubMed ID: 20226525
[TBL] [Abstract][Full Text] [Related]
13. Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients.
Romeo M; Chauffaille Mde L; Silva MR; Bahia DM; Kerbauy J
Leuk Res; 2002 Nov; 26(11):993-6. PubMed ID: 12363467
[TBL] [Abstract][Full Text] [Related]
14. Fluorescence in situ hybridization: molecular probes for diagnosis of pediatric neoplastic diseases.
Raimondi SC
Cancer Invest; 2000; 18(2):135-47. PubMed ID: 10705876
[TBL] [Abstract][Full Text] [Related]
15. [Tumor cytogenetics].
Fonatsch C; Krömer E
Wien Med Wochenschr; 2005 Jun; 155(11-12):281-8. PubMed ID: 16035389
[TBL] [Abstract][Full Text] [Related]
16. Population-based characterization of the genetic landscape of chronic lymphocytic leukemia patients referred for cytogenetic testing in British Columbia, Canada: the role of provincial laboratory standardization.
Gerrie AS; Huang SJ; Bruyere H; Dalal C; Hrynchak M; Karsan A; Ramadan KM; Smith AC; Tyson C; Toze CL; Gillan TL
Cancer Genet; 2014; 207(7-8):316-25. PubMed ID: 25441686
[TBL] [Abstract][Full Text] [Related]
17. Applications of Fluorescence In Situ Hybridization Technology in Malignancies.
Tansatit M
Methods Mol Biol; 2017; 1541():75-90. PubMed ID: 27910016
[TBL] [Abstract][Full Text] [Related]
18. Reporting of Diagnostic Cytogenetic Results.
Giersch ABS; Bieber FR; Dubuc AM; Fletcher JA; Ligon AH; Mason-Suares H; Morton CC; Weremowicz S; Xiao S; Cin PD
Curr Protoc Hum Genet; 2016 Apr; 89():A.1D.1-A.1D.23. PubMed ID: 27037490
[TBL] [Abstract][Full Text] [Related]
19. Clinical utilization of high-resolution single nucleotide polymorphism based oligonucleotide arrays in diagnostic studies of pediatric patients with solid tumors.
Dougherty MJ; Tooke LS; Sullivan LM; Hakonarson H; Wainwright LM; Biegel JA
Cancer Genet; 2012; 205(1-2):42-54. PubMed ID: 22429597
[TBL] [Abstract][Full Text] [Related]
20. Molecular cytogenetics in solid tumors: laboratorial tool for diagnosis, prognosis, and therapy.
Varella-Garcia M
Oncologist; 2003; 8(1):45-58. PubMed ID: 12604731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
